Hydrogen Gas Therapy: From Preclinical Studies to Clinical Trials

Executive summary

This review is included to make one distinction unmistakable: the serious clinical research on inhaled hydrogen is emergency and transplant medicine, not wellness.

The authors report that mounting evidence indicates hydrogen gas is a versatile therapeutic agent even at very low, non-combustible concentrations, and note that the Chinese National Health and Medical Commission recommended the use of inhaled hydrogen in addition to oxygen therapy in the treatment of COVID-19-associated pneumonia.

They highlight findings from preclinical research and clinical studies showing that hydrogen reduces the organ damage caused by ischaemia-reperfusion, and outline the role this plays in medical emergencies including myocardial infarction, haemorrhagic shock and out-of-hospital cardiac arrest, as well as in organ transplantation.

Hydrogen is compared with established treatments such as targeted temperature management, and possible mechanisms are discussed, including suppression of TNF-α-mediated endothelial glycocalyx degradation by inhaled hydrogen. The authors also describe a method enabling hydrogen gas to be transported to emergency settings and injected into organ preservation solution at the site of donor organ procurement.

Their conclusion is that hydrogen is an easily administered, inexpensive and well-tolerated agent that is highly effective for a wide range of conditions in emergency medicine, as well as for preserving donated organs. Every one of those settings involves clinicians, monitoring and acute pathology.

Why this research matters

Hydrogen inhalation equipment sold for home use borrows credibility from research like this. Reading it shows how far the actual clinical work sits from a wellness context.

It also demonstrates that the mechanism is taken seriously by mainstream clinical researchers - which is a fair point in the technology's favour, provided the context is not stripped away.

What the researchers found

The review reports mounting evidence that hydrogen gas is a versatile therapeutic agent at very low, non-combustible concentrations, with anti-tumour, anti-inflammatory and antioxidant actions described.

Key findings highlighted are that hydrogen reduces organ damage caused by ischaemia-reperfusion, with relevance to myocardial infarction, haemorrhagic shock, out-of-hospital cardiac arrest and organ transplantation.

The Chinese National Health and Medical Commission recommended the use of inhaled hydrogen in addition to oxygen therapy in the treatment of COVID-19-associated pneumonia.

A proposed mechanism is the suppression of TNF-α-mediated endothelial glycocalyx degradation by inhaled hydrogen.

The authors conclude hydrogen is easily administered, inexpensive and well-tolerated, and highly effective for a range of conditions in emergency medicine and for preserving donated organs. No pooled effect estimates are generated and none are reproduced here.

What the results mean

Inhaled hydrogen has a plausible mechanism and is under genuine clinical investigation in acute medicine. That is a legitimate scientific position and it should not be dismissed.

It is also entirely disconnected from what a consumer buys. Reducing reperfusion injury after cardiac arrest, delivered by clinicians to a patient under monitoring, tells you nothing about breathing hydrogen through a cannula at home for general wellbeing.

The word 'effective' in the authors' conclusion applies to the emergency medicine contexts they reviewed. Transplanting that word to a wellness setting is the error this entry exists to prevent.

Strengths and limitations

Strengths

• Written by clinical researchers actively working on hydrogen in emergency medicine.
• Clear mechanistic proposal centred on ischaemia-reperfusion injury.
• Compares hydrogen against an established treatment rather than presenting it in isolation.
• Covers practical administration and transport challenges honestly.
• Notes a national health authority recommendation with its specific indication attached.

Limitations

• Narrative review with no systematic protocol or bias assessment.
• No pooled estimates, study counts or sample sizes reported in the source abstract.
• Clinical contexts are acute and supervised, limiting relevance to consumer use.
• Does not address general wellness applications at all.
• Authors are closely associated with the research programme reviewed.

Evidence in context

The 2023 review of human clinical studies counted 81 trials across many disease areas and closed by asking whether hydrogen will become a drug substance in future practice - which places this emergency-medicine work within a still-unresolved field.

On the consumer-relevant side, a 2021 randomised pilot trial of hydrogen-rich water in older adults found significant changes in a small number of biomarkers and no significant differences on most outcomes.

The gap between the acute clinical research described here and the consumer wellness market has not narrowed.

Related research

1. Molecular hydrogen therapy - a review on clinical studies and outcomes Johnsen HM, Hiorth M, Klaveness J. Molecules 28(23):7785. 2023. PMID 38067515; PMC10707987; doi:10.3390/molecules28237785.Counts and characterises the whole human clinical literature, placing this work in context.
2. The effects of 6-month hydrogen-rich water intake on molecular and phenotypic biomarkers of aging in older adults aged 70 years and over: a randomized controlled pilot trial Zanini D, Todorovic N, Korovljev D, et al. Experimental Gerontology 155:111574. 2021. PMID 34601077; doi:10.1016/j.exger.2021.111574.The hydrogen-rich water pilot trial - the route most consumer equipment actually delivers.
3. General wellness: policy for low risk devices - guidance for industry and FDA staff U.S. FDA, Center for Devices and Radiological Health. Docket FDA-2014-N-1039. 2019. CDRH guidance.FDA guidance on the boundary between general wellness products and regulated medical devices.
4. Health products compliance guidance U.S. Federal Trade Commission, Bureau of Consumer Protection. 2022. Replaces the 1998 Dietary Supplements advertising guide.FTC substantiation standard for health claims in advertising.